Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 2
1970 1
1971 2
1972 6
1973 17
1974 14
1975 23
1976 21
1977 26
1978 10
1979 15
1980 19
1981 20
1982 9
1983 18
1984 12
1985 8
1986 13
1987 14
1988 12
1989 9
1990 18
1991 20
1992 3
1993 12
1994 6
1995 11
1996 5
1997 6
1998 12
1999 7
2000 14
2001 8
2002 14
2003 28
2004 35
2005 38
2006 47
2007 63
2008 47
2009 60
2010 81
2011 102
2012 131
2013 127
2014 120
2015 155
2016 199
2017 264
2018 346
2019 520
2020 582
Text availability
Article attribute
Article type
Publication date

Search Results

2,991 results
Results by year
Filters applied: . Clear all
Page 1
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM; GWPCARE3 Study Group. Devinsky O, et al. N Engl J Med. 2018 May 17;378(20):1888-1897. doi: 10.1056/NEJMoa1714631. N Engl J Med. 2018. PMID: 29768152 Free article. Clinical Trial.
RESULTS: A total of 225 patients were enrolled; 76 patients were assigned to the 20-mg cannabidiol group, 73 to the 10-mg cannabidiol group, and 76 to the placebo group. ...The median percent reduction from baseline in drop-seizure frequency during the treatment per …
RESULTS: A total of 225 patients were enrolled; 76 patients were assigned to the 20-mg cannabidiol group, 73 to the 10-mg cannabid
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.
Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S; Cannabidiol in Dravet Syndrome Study Group. Devinsky O, et al. N Engl J Med. 2017 May 25;376(21):2011-2020. doi: 10.1056/NEJMoa1611618. N Engl J Med. 2017. PMID: 28538134 Free article. Clinical Trial.
The percentage of patients who became seizure-free was 5% with cannabidiol and 0% with placebo (P=0.08). Adverse events that occurred more frequently in the cannabidiol group than in the placebo group included diarrhea, vomiting, fatigue, pyrexia, somnolence, and ab …
The percentage of patients who became seizure-free was 5% with cannabidiol and 0% with placebo (P=0.08). Adverse events that occurred …
Cannabidiol: State of the art and new challenges for therapeutic applications.
Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, Laezza C, Bifulco M. Pisanti S, et al. Pharmacol Ther. 2017 Jul;175:133-150. doi: 10.1016/j.pharmthera.2017.02.041. Epub 2017 Feb 22. Pharmacol Ther. 2017. PMID: 28232276 Review.
Δ(9)-THC and cannabidiol (CBD) are the most abundant phytocannabinoids in Cannabis plants and therapeutic application for both compounds have been suggested. ...Furthermore, the therapeutic potential of cannabidiol is also highlighted, in particular in nuerological …
Δ(9)-THC and cannabidiol (CBD) are the most abundant phytocannabinoids in Cannabis plants and therapeutic application for both compou …
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C, Sommerville K; GWPCARE4 Study Group. Thiele EA, et al. Lancet. 2018 Mar 17;391(10125):1085-1096. doi: 10.1016/S0140-6736(18)30136-3. Epub 2018 Jan 26. Lancet. 2018. PMID: 29395273 Clinical Trial.
No controlled studies have investigated the use of cannabidiol for patients with seizures associated with Lennox-Gastaut syndrome. ...One patient (1%) died in the cannabidiol group, but this was considered unrelated to treatment. INTERPRETATION: Add-on cannabidio
No controlled studies have investigated the use of cannabidiol for patients with seizures associated with Lennox-Gastaut syndrome. .. …
Cannabidiol, neuroprotection and neuropsychiatric disorders.
Campos AC, Fogaça MV, Sonego AB, Guimarães FS. Campos AC, et al. Pharmacol Res. 2016 Oct;112:119-127. doi: 10.1016/j.phrs.2016.01.033. Epub 2016 Feb 1. Pharmacol Res. 2016. PMID: 26845349 Review.
Cannabidiol (CBD) is a non-psychotomimetic phytocannabinoid derived from Cannabis sativa. It has possible therapeutic effects over a broad range of neuropsychiatric disorders. ...
Cannabidiol (CBD) is a non-psychotomimetic phytocannabinoid derived from Cannabis sativa. It has possible therapeutic effects over a
Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy.
Samanta D. Samanta D. Pediatr Neurol. 2019 Jul;96:24-29. doi: 10.1016/j.pediatrneurol.2019.03.014. Epub 2019 Mar 22. Pediatr Neurol. 2019. PMID: 31053391 Review.
Among the two most common cannabinoids, cannabidiol has better antiepileptic potential than tetrahydrocannabinol. The exact antiepileptic mechanism of cannabidiol is currently not known, but it modulates a number of endogenous systems and may have a novel anticonvul …
Among the two most common cannabinoids, cannabidiol has better antiepileptic potential than tetrahydrocannabinol. The exact antiepile …
Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.
Crippa JA, Guimarães FS, Campos AC, Zuardi AW. Crippa JA, et al. Front Immunol. 2018 Sep 21;9:2009. doi: 10.3389/fimmu.2018.02009. eCollection 2018. Front Immunol. 2018. PMID: 30298064 Free PMC article. Review.
Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a compound that does not produce the typical subjective effects of marijuana. Objectives: The aim of the present review is to describe the main advances in the development of the experiment …
Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a compound that does not produce the typical subj …
Antioxidative and Anti-Inflammatory Properties of Cannabidiol.
Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Atalay S, et al. Antioxidants (Basel). 2019 Dec 25;9(1):21. doi: 10.3390/antiox9010021. Antioxidants (Basel). 2019. PMID: 31881765 Free PMC article. Review.
Cannabidiol (CBD) is one of the main pharmacologically active phytocannabinoids of Cannabis sativa L. CBD is non-psychoactive but exerts a number of beneficial pharmacological effects, including anti-inflammatory and antioxidant properties. ...
Cannabidiol (CBD) is one of the main pharmacologically active phytocannabinoids of Cannabis sativa L. CBD is non-psychoactive but exe
Cannabis and epilepsy.
Thomas RH, Cunningham MO. Thomas RH, et al. Pract Neurol. 2018 Dec;18(6):465-471. doi: 10.1136/practneurol-2018-002058. Epub 2018 Oct 18. Pract Neurol. 2018. PMID: 30337476 Review.
It is quite possible that cannabidiol, licensed in the USA for treating rare genetic epilepsies, may open the door for the widespread legalisation of recreational cannabis. It is important that neurologists understand the difference between artisanal cannabidiol pro …
It is quite possible that cannabidiol, licensed in the USA for treating rare genetic epilepsies, may open the door for the widespread …
The growing trend of cannabidiol in skincare products.
Jhawar N, Schoenberg E, Wang JV, Saedi N. Jhawar N, et al. Clin Dermatol. 2019 May-Jun;37(3):279-281. doi: 10.1016/j.clindermatol.2018.11.002. Epub 2018 Nov 29. Clin Dermatol. 2019. PMID: 31178109
Recently, cannabidiol has garnered considerable attention in the public and media as a trendy and popular ingredient in skincare products. Cannabidiol is a cannabinoid that lacks psychoactive properties. It has been marketed to consumers as being antiinflammatory, a …
Recently, cannabidiol has garnered considerable attention in the public and media as a trendy and popular ingredient in skincare prod …
2,991 results
Jump to page
Feedback